In patients with acquired hypothalamic obesity, setmelanotide reduced BMI at 52 weeks compared with placebo, according to results of the TRANSCEND trial presented at ENDO 2025. For the phase 3 trial, ...

Obesity-related cancer deaths increased more than threefold between 1999 and 2020, according to an analysis of the CDC WONDER ...

Data from a limited number of trials hint that GLP-1 use might improve erectile dysfunction and testosterone levels for men, but more research is needed to provide a clearer picture, researchers ...

Due to a lack of sufficient malpractice liability coverage and the steadily increasing value of professional sports contracts ...

At Clinical Trials at the Summit, Dante Pieramici, MD, discusses the use of automated imaging aggregation and AI to improve ...

Managing rheumatoid arthritis-associated osteoporosis requires an ongoing, multidisciplinary effort to prevent bone loss, fractures and falls, according to experts.“Osteoporosis is a ...

During reproductive transitions such as postpartum and menopause, a high level of oxytocin may reduce negative mood effects ...

An oral melanocortin-4 receptor agonist conferred significant BMI reductions among adolescents and adults with hypothalamic ...

A once-weekly growth hormone therapy improved growth-related endpoints for adolescents with multiple conditions of short ...

In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...